Attn Newbies ( I know a rare bird for this stock) are well advised to understand the significance of this particular news release.
Euphas is a 10+ year study of PMX use in Sepsis cases.
Reports 28-day mortality of just 36% for patients undergoing PMX hemoadsorption versus
75% predicted by widely accepted SAPS II mortality estimation tool
oing PMX hemoadsorption versus
75% predicted by widely accepted SAPS II mortality estimation tool
https://stockhouse.com/news/press-releases/2023/04/18/spectral-medical-announces-positive-results-of-euphas-2-clinical-trial
Dr. John Kellum, Chief Medical Officer of Spectral Medical, stated, “We were pleased to see that this cohort of patients with high EAA, 0.75 (0.65-0.81), and high severity of illness (APACHE II 26, SAPS II 67.5) achieved a hospital survival rate of 64% with PMX therapy. The results of the EUPHAS-2 study confirm our results from the US subgroup enrolled in the EUPHRATES trial who also had significant organ failure (multiple organ dysfunction score >9) and EAA between 0.6 and 0.89. In this intent-to-treat cohort of 179 patients, 28-day mortality was 36.7%. Furthermore, as seen in EUPHAS-2 in patients with decreasing EAA, recovery from septic shock was faster. We are currently prospectively studying PMX therapy compared to standard of care in patients with very similar disease severity (and EAA levels) to those enrolled in the EUPHAS 2 study.”